Researchers have developed an integrated hydrodynamic forecasting framework that accurately predicts urban flood inundation ...
Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...
The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...
The FDA has approved the first RAS-targeted therapy for metastatic pancreatic cancer, offering a new treatment option for patients with previously treated disease. Daraxonrasib (Rasonque, Revolution ...
Unmanned Surface Vessel Division 12 (Sea Hunter) and 13 (Sea Hunter) conduct unit level training underway in San Diego Bay, California, May 1, 2025. US Navy photo The Navy’s portfolio acquisition ...
HEC Date Source Diagnostic is a Linux and Python desktop utility for examining disagreements between a computer's displayed date and time, Python's clock, the Linux timezone configuration, the ...
b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Data from the phase 1/2 RMC-6236-001 trial show that the RAS(ON) multiselective inhibitor daraxonrasib yielded responses in pretreated RAS-mutated PDAC. In the phase 1/2 trial, daraxonrasib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results